# Randomised Study to Compare the Efficacy of AZD6244 vs TMZ

> **NCT00338130** · PHASE2 · COMPLETED · sponsor: **AstraZeneca** · enrollment: 239 (actual)

## Conditions studied

- Melanoma

## Interventions

- **DRUG:** AZD6244
- **DRUG:** Temozolomide

## Key facts

- **NCT ID:** NCT00338130
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-07
- **Primary completion:** 2007-09
- **Final completion:** 2013-07
- **Target enrollment:** 239 (ACTUAL)
- **Last updated:** 2014-08-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00338130

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00338130, "Randomised Study to Compare the Efficacy of AZD6244 vs TMZ". Retrieved via AI Analytics 2026-06-10 from https://api.ai-analytics.org/clinical/NCT00338130. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*